An Australian stem cell and regenerative medicine company

May 02, 2024

JMM & Ethica Capital Innovation & Investment Insights Lunch

In case you missed it, Dr Kilian Kelly presented to brokers, fund managers, and high net-worth investors over lunch at the Establishment Ballroom, outlining Cynata's recent clinical trial milestones. Watch the presentation here:

March 14, 2024

FNN interview with Dr Kilian Kelly

Off the back of a string of positive announcements - DFU trial initial data, new CBO and first patient treated in aGVHD trial - Cynata CEO Dr Kilian Kelly sat down with Finance News Network to discuss The Company's milestones. Watch the interview below

FNN Logo

March 05, 2024

Cynata Therapeutics treats first patient in aGvHD clinical trial

In early March, the first patient was enrolled and treated in Cynata’s Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).

Learn more here: https://bit.ly/4b0nkG7

February 26, 2024

Cynata say their diabetic foot ulcer trial is going great guns

Cynata has updated the market on the positive progress of its diabetic foot ulcers clinical trial.

Read Stockhead’s coverage here https://bit.ly/3P0mb8N 

December 28, 2023

Cynata expects DFU trial results in Q1 2024

Cynata is analysing wound surface areas in the first 16 patients of its Phase 1 trial for CYP-006TK, its off-the-shelf iPSC-derived MSC topical dressing for diabetic foot ulcers, with results expected by Q1 2024.

Understand more here